Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines

This article was originally published here

The company was founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine (Cell

The post Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply